Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 173

1.

T cell-derived soluble glycoprotein GPIbα mediates PGE2 production in human monocytes activated with the vaccine adjuvant MDP.

Liu F, Endo Y, Romantseva T, Wu WW, Akue A, Shen RF, Golding H, Zaitseva M.

Sci Signal. 2019 Oct 8;12(602). pii: eaat6023. doi: 10.1126/scisignal.aat6023.

PMID:
31594856
2.

Antibiotics-Driven Gut Microbiome Perturbation Alters Immunity to Vaccines in Humans.

Hagan T, Cortese M, Rouphael N, Boudreau C, Linde C, Maddur MS, Das J, Wang H, Guthmiller J, Zheng NY, Huang M, Uphadhyay AA, Gardinassi L, Petitdemange C, McCullough MP, Johnson SJ, Gill K, Cervasi B, Zou J, Bretin A, Hahn M, Gewirtz AT, Bosinger SE, Wilson PC, Li S, Alter G, Khurana S, Golding H, Pulendran B.

Cell. 2019 Sep 5;178(6):1313-1328.e13. doi: 10.1016/j.cell.2019.08.010.

PMID:
31491384
3.

Repeat vaccination reduces antibody affinity maturation across different influenza vaccine platforms in humans.

Khurana S, Hahn M, Coyle EM, King LR, Lin TL, Treanor J, Sant A, Golding H.

Nat Commun. 2019 Jul 26;10(1):3338. doi: 10.1038/s41467-019-11296-5.

4.

Antibody-dependent enhancement of influenza disease promoted by increase in hemagglutinin stem flexibility and virus fusion kinetics.

Winarski KL, Tang J, Klenow L, Lee J, Coyle EM, Manischewitz J, Turner HL, Takeda K, Ward AB, Golding H, Khurana S.

Proc Natl Acad Sci U S A. 2019 Jul 23;116(30):15194-15199. doi: 10.1073/pnas.1821317116. Epub 2019 Jul 11.

PMID:
31296560
5.

Differential human antibody repertoires following Zika infection and the implications for serodiagnostics and disease outcome.

Ravichandran S, Hahn M, Belaunzarán-Zamudio PF, Ramos-Castañeda J, Nájera-Cancino G, Caballero-Sosa S, Navarro-Fuentes KR, Ruiz-Palacios G, Golding H, Beigel JH, Khurana S.

Nat Commun. 2019 Apr 26;10(1):1943. doi: 10.1038/s41467-019-09914-3.

6.

Prolonged evolution of the memory B cell response induced by a replicating adenovirus-influenza H5 vaccine.

Matsuda K, Huang J, Zhou T, Sheng Z, Kang BH, Ishida E, Griesman T, Stuccio S, Bolkhovitinov L, Wohlbold TJ, Chromikova V, Cagigi A, Leung K, Andrews S, Cheung CSF, Pullano AA, Plyler J, Soto C, Zhang B, Yang Y, Joyce MG, Tsybovsky Y, Wheatley A, Narpala SR, Guo Y, Darko S, Bailer RT, Poole A, Liang CJ, Smith J, Alexander J, Gurwith M, Migueles SA, Koup RA, Golding H, Khurana S, McDermott AB, Shapiro L, Krammer F, Kwong PD, Connors M.

Sci Immunol. 2019 Apr 19;4(34). pii: eaau2710. doi: 10.1126/sciimmunol.aau2710.

PMID:
31004012
7.

Broad Hemagglutinin-Specific Memory B Cell Expansion by Seasonal Influenza Virus Infection Reflects Early-Life Imprinting and Adaptation to the Infecting Virus.

Tesini BL, Kanagaiah P, Wang J, Hahn M, Halliley JL, Chaves FA, Nguyen PQT, Nogales A, DeDiego ML, Anderson CS, Ellebedy AH, Strohmeier S, Krammer F, Yang H, Bandyopadhyay S, Ahmed R, Treanor JJ, Martinez-Sobrido L, Golding H, Khurana S, Zand MS, Topham DJ, Sangster MY.

J Virol. 2019 Apr 3;93(8). pii: e00169-19. doi: 10.1128/JVI.00169-19. Print 2019 Apr 15.

8.

AS03-adjuvanted H5N1 vaccine promotes antibody diversity and affinity maturation, NAI titers, cross-clade H5N1 neutralization, but not H1N1 cross-subtype neutralization.

Khurana S, Coyle EM, Manischewitz J, King LR, Gao J, Germain RN, Schwartzberg PL, Tsang JS, Golding H; and the CHI Consortium.

NPJ Vaccines. 2018 Oct 1;3:40. doi: 10.1038/s41541-018-0076-2. eCollection 2018.

9.

Protective antigenic sites in respiratory syncytial virus G attachment protein outside the central conserved and cysteine noose domains.

Lee J, Klenow L, Coyle EM, Golding H, Khurana S.

PLoS Pathog. 2018 Aug 24;14(8):e1007262. doi: 10.1371/journal.ppat.1007262. eCollection 2018 Aug.

10.

A Potent Germline-like Human Monoclonal Antibody Targets a pH-Sensitive Epitope on H7N9 Influenza Hemagglutinin.

Yu F, Song H, Wu Y, Chang SY, Wang L, Li W, Hong B, Xia S, Wang C, Khurana S, Feng Y, Wang Y, Sun Z, He B, Hou D, Manischewitz J, King LR, Song Y, Min JY, Golding H, Ji X, Lu L, Jiang S, Dimitrov DS, Ying T.

Cell Host Microbe. 2017 Oct 11;22(4):471-483.e5. doi: 10.1016/j.chom.2017.08.011. Epub 2017 Sep 28.

11.

Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy.

Goswami M, Prince G, Biancotto A, Moir S, Kardava L, Santich BH, Cheung F, Kotliarov Y, Chen J, Shi R, Zhou H, Golding H, Manischewitz J, King L, Kunz LM, Noonan K, Borrello IM, Smith BD, Hourigan CS.

J Transl Med. 2017 Jul 10;15(1):155. doi: 10.1186/s12967-017-1252-2.

12.

Development of an animal model of progressive vaccinia in nu/nu mice and the use of bioluminescence imaging for assessment of the efficacy of monoclonal antibodies against vaccinial B5 and L1 proteins.

Zaitseva M, Thomas A, Meseda CA, Cheung CYK, Diaz CG, Xiang Y, Crotty S, Golding H.

Antiviral Res. 2017 Aug;144:8-20. doi: 10.1016/j.antiviral.2017.05.002. Epub 2017 May 8.

PMID:
28495463
13.

A systematic review and meta-analysis of cross-reactivity of antibodies induced by oil-in-water emulsion adjuvanted influenza H5N1 virus monovalent vaccines.

Chada KE, Forshee R, Golding H, Anderson S, Yang H.

Vaccine. 2017 May 31;35(24):3162-3170. doi: 10.1016/j.vaccine.2017.04.029. Epub 2017 May 5. Review.

PMID:
28483200
14.

What Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans? The Importance of Bridging Studies and Species-Independent Correlates of Protection.

Golding H, Khurana S, Zaitseva M.

Cold Spring Harb Perspect Biol. 2018 Apr 2;10(4). pii: a028902. doi: 10.1101/cshperspect.a028902. Review.

PMID:
28348035
15.

Preclinical evaluation of bacterially produced RSV-G protein vaccine: Strong protection against RSV challenge in cotton rat model.

Fuentes S, Klenow L, Golding H, Khurana S.

Sci Rep. 2017 Feb 10;7:42428. doi: 10.1038/srep42428.

16.

Preexisting Immunity, Not Frailty Phenotype, Predicts Influenza Postvaccination Titers among Older Veterans.

Van Epps P, Tumpey T, Pearce MB, Golding H, Higgins P, Hornick T, Burant C, Wilson BM, Banks R, Gravenstein S, Canaday DH.

Clin Vaccine Immunol. 2017 Mar 6;24(3). pii: e00498-16. doi: 10.1128/CVI.00498-16. Print 2017 Mar.

17.

Development of bioluminescence imaging of respiratory syncytial virus (RSV) in virus-infected live mice and its use for evaluation of therapeutics and vaccines.

Fuentes S, Arenas D, Moore MM, Golding H, Khurana S.

Vaccine. 2017 Jan 23;35(4):694-702. doi: 10.1016/j.vaccine.2016.11.044. Epub 2016 Dec 15.

PMID:
27989627
18.

Antigenic Fingerprinting of Antibody Response in Humans following Exposure to Highly Pathogenic H7N7 Avian Influenza Virus: Evidence for Anti-PA-X Antibodies.

Khurana S, Chung KY, Coyle EM, Meijer A, Golding H.

J Virol. 2016 Sep 29;90(20):9383-93. doi: 10.1128/JVI.01408-16. Print 2016 Oct 15.

19.

ICOS(+)PD-1(+)CXCR3(+) T follicular helper cells contribute to the generation of high-avidity antibodies following influenza vaccination.

Bentebibel SE, Khurana S, Schmitt N, Kurup P, Mueller C, Obermoser G, Palucka AK, Albrecht RA, Garcia-Sastre A, Golding H, Ueno H.

Sci Rep. 2016 May 27;6:26494. doi: 10.1038/srep26494.

20.

Production of Potent Fully Human Polyclonal Antibodies against Ebola Zaire Virus in Transchromosomal Cattle.

Dye JM, Wu H, Hooper JW, Khurana S, Kuehne AI, Coyle EM, Ortiz RA, Fuentes S, Herbert AS, Golding H, Bakken RA, Brannan JM, Kwilas SA, Sullivan EJ, Luke TC, Smith G, Glenn G, Li W, Ye L, Yang C, Compans RW, Tripp RA, Jiao JA.

Sci Rep. 2016 Apr 25;6:24897. doi: 10.1038/srep24897.

21.

Antigenic Fingerprinting following Primary RSV Infection in Young Children Identifies Novel Antigenic Sites and Reveals Unlinked Evolution of Human Antibody Repertoires to Fusion and Attachment Glycoproteins.

Fuentes S, Coyle EM, Beeler J, Golding H, Khurana S.

PLoS Pathog. 2016 Apr 21;12(4):e1005554. doi: 10.1371/journal.ppat.1005554. eCollection 2016 Apr.

22.

Patients with MS under daclizumab therapy mount normal immune responses to influenza vaccination.

Lin YC, Winokur P, Blake A, Wu T, Manischewitz J, King LR, Romm E, Golding H, Bielekova B.

Neurol Neuroimmunol Neuroinflamm. 2016 Jan 27;3(1):e196. doi: 10.1212/NXI.0000000000000196. eCollection 2016 Feb.

23.

A Simple Flow-Cytometric Method Measuring B Cell Surface Immunoglobulin Avidity Enables Characterization of Affinity Maturation to Influenza A Virus.

Frank GM, Angeletti D, Ince WL, Gibbs JS, Khurana S, Wheatley AK, Max EE, McDermott AB, Golding H, Stevens J, Bennink JR, Yewdell JW.

MBio. 2015 Aug 4;6(4):e01156. doi: 10.1128/mBio.01156-15.

24.

ISCOMATRIX™ adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans.

Chung KY, Coyle EM, Jani D, King LR, Bhardwaj R, Fries L, Smith G, Glenn G, Golding H, Khurana S.

Vaccine. 2015 Jul 31;33(32):3953-62. doi: 10.1016/j.vaccine.2015.06.047. Epub 2015 Jun 17.

PMID:
26093202
25.
26.

High-Affinity H7 Head and Stalk Domain-Specific Antibody Responses to an Inactivated Influenza H7N7 Vaccine After Priming With Live Attenuated Influenza Vaccine.

Halliley JL, Khurana S, Krammer F, Fitzgerald T, Coyle EM, Chung KY, Baker SF, Yang H, Martínez-Sobrido L, Treanor JJ, Subbarao K, Golding H, Topham DJ, Sangster MY.

J Infect Dis. 2015 Oct 15;212(8):1270-8. doi: 10.1093/infdis/jiv210. Epub 2015 Apr 2.

27.

Oral priming with replicating adenovirus serotype 4 followed by subunit H5N1 vaccine boost promotes antibody affinity maturation and expands H5N1 cross-clade neutralization.

Khurana S, Coyle EM, Manischewitz J, King LR, Ishioka G, Alexander J, Smith J, Gurwith M, Golding H.

PLoS One. 2015 Jan 28;10(1):e0115476. doi: 10.1371/journal.pone.0115476. eCollection 2015.

28.

Postchallenge administration of brincidofovir protects healthy and immune-deficient mice reconstituted with limited numbers of T cells from lethal challenge with IHD-J-Luc vaccinia virus.

Zaitseva M, McCullough KT, Cruz S, Thomas A, Diaz CG, Keilholz L, Grossi IM, Trost LC, Golding H.

J Virol. 2015 Mar;89(6):3295-307. doi: 10.1128/JVI.03340-14. Epub 2015 Jan 14.

29.

Live attenuated influenza A virus vaccine protects against A(H1N1)pdm09 heterologous challenge without vaccine associated enhanced respiratory disease.

Gauger PC, Loving CL, Khurana S, Lorusso A, Perez DR, Kehrli ME Jr, Roth JA, Golding H, Vincent AL.

Virology. 2014 Dec;471-473:93-104. doi: 10.1016/j.virol.2014.10.003. Epub 2014 Oct 28.

30.

H5 N-terminal β sheet promotes oligomerization of H7-HA1 that induces better antibody affinity maturation and enhanced protection against H7N7 and H7N9 viruses compared to inactivated influenza vaccine.

Khurana S, Coyle EM, Verma S, King LR, Manischewitz J, Crevar CJ, Carter DM, Ross TM, Golding H.

Vaccine. 2014 Nov 12;32(48):6421-32. doi: 10.1016/j.vaccine.2014.09.049. Epub 2014 Oct 3.

PMID:
25284811
31.

Differences in PGE2 production between primary human monocytes and differentiated macrophages: role of IL-1β and TRIF/IRF3.

Endo Y, Blinova K, Romantseva T, Golding H, Zaitseva M.

PLoS One. 2014 May 28;9(5):e98517. doi: 10.1371/journal.pone.0098517. eCollection 2014.

32.

Heterologous prime-boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization.

Khurana S, Coyle EM, Dimitrova M, Castellino F, Nicholson K, Del Giudice G, Golding H.

PLoS One. 2014 Apr 22;9(4):e95496. doi: 10.1371/journal.pone.0095496. eCollection 2014.

33.

Global analyses of human immune variation reveal baseline predictors of postvaccination responses.

Tsang JS, Schwartzberg PL, Kotliarov Y, Biancotto A, Xie Z, Germain RN, Wang E, Olnes MJ, Narayanan M, Golding H, Moir S, Dickler HB, Perl S, Cheung F; Baylor HIPC Center; CHI Consortium.

Cell. 2014 Apr 10;157(2):499-513. doi: 10.1016/j.cell.2014.03.031. Erratum in: Cell. 2014 Jul 3;158(1):226.

34.

Novel antibody-independent receptor-binding SPR-based assay for rapid measurement of influenza vaccine potency.

Khurana S, King LR, Manischewitz J, Coyle EM, Golding H.

Vaccine. 2014 Apr 17;32(19):2188-97. doi: 10.1016/j.vaccine.2014.02.049. Epub 2014 Mar 6.

PMID:
24613520
35.

A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response.

Talaat KR, Luke CJ, Khurana S, Manischewitz J, King LR, McMahon BA, Karron RA, Lewis KD, Qin J, Follmann DA, Golding H, Neuzil KM, Subbarao K.

J Infect Dis. 2014 Jun 15;209(12):1860-9. doi: 10.1093/infdis/jiu123. Epub 2014 Mar 5. Erratum in: J Infect Dis. 2014 Dec 15;210(12):2021.

36.

Predictive markers of safety and immunogenicity of adjuvanted vaccines.

Mastelic B, Garçon N, Del Giudice G, Golding H, Gruber M, Neels P, Fritzell B.

Biologicals. 2013 Nov;41(6):458-68. doi: 10.1016/j.biologicals.2013.08.006. Epub 2013 Sep 23.

PMID:
24071553
37.

Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease.

Khurana S, Loving CL, Manischewitz J, King LR, Gauger PC, Henningson J, Vincent AL, Golding H.

Sci Transl Med. 2013 Aug 28;5(200):200ra114. doi: 10.1126/scitranslmed.3006366.

38.

Influenza A virus hemagglutinin trimerization completes monomer folding and antigenicity.

Magadán JG, Khurana S, Das SR, Frank GM, Stevens J, Golding H, Bennink JR, Yewdell JW.

J Virol. 2013 Sep;87(17):9742-53. doi: 10.1128/JVI.00471-13. Epub 2013 Jul 3.

39.

Getting to the heart of influenza.

Yewdell JW, Spiro DJ, Golding H, Quill H, Mittelman A, Nabel GJ.

Sci Transl Med. 2013 Jun 26;5(191):191ed8. doi: 10.1126/scitranslmed.3006735. No abstract available.

40.
41.

DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults.

Khurana S, Wu J, Dimitrova M, King LR, Manischewitz J, Graham BS, Ledgerwood JE, Golding H.

J Infect Dis. 2013 Aug 1;208(3):413-7. doi: 10.1093/infdis/jit178. Epub 2013 Apr 30.

42.

Effects of postchallenge administration of ST-246 on dissemination of IHD-J-Luc vaccinia virus in normal mice and in immune-deficient mice reconstituted with T cells.

Zaitseva M, Shotwell E, Scott J, Cruz S, King LR, Manischewitz J, Diaz CG, Jordan RA, Grosenbach DW, Golding H.

J Virol. 2013 May;87(10):5564-76. doi: 10.1128/JVI.03426-12. Epub 2013 Mar 6.

43.

Potential use of inflammation and early immunological event biomarkers in assessing vaccine safety.

Mastelic B, Lewis DJ, Golding H, Gust I, Sheets R, Lambert PH.

Biologicals. 2013 Mar;41(2):115-24. doi: 10.1016/j.biologicals.2012.10.005. Epub 2012 Nov 27.

PMID:
23194656
44.

Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody.

Schmidt AG, Xu H, Khan AR, O'Donnell T, Khurana S, King LR, Manischewitz J, Golding H, Suphaphiphat P, Carfi A, Settembre EC, Dormitzer PR, Kepler TB, Zhang R, Moody MA, Haynes BF, Liao HX, Shaw DE, Harrison SC.

Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):264-9. doi: 10.1073/pnas.1218256109. Epub 2012 Nov 21.

45.

Heterovariant cross-reactive B-cell responses induced by the 2009 pandemic influenza virus A subtype H1N1 vaccine.

He XS, Sasaki S, Baer J, Khurana S, Golding H, Treanor JJ, Topham DJ, Sangster MY, Jin H, Dekker CL, Subbarao K, Greenberg HB.

J Infect Dis. 2013 Jan 15;207(2):288-96. doi: 10.1093/infdis/jis664. Epub 2012 Oct 29.

46.

Humans with chronic granulomatous disease maintain humoral immunologic memory despite low frequencies of circulating memory B cells.

Moir S, De Ravin SS, Santich BH, Kim JY, Posada JG, Ho J, Buckner CM, Wang W, Kardava L, Garofalo M, Marciano BE, Manischewitz J, King LR, Khurana S, Chun TW, Golding H, Fauci AS, Malech HL.

Blood. 2012 Dec 6;120(24):4850-8. doi: 10.1182/blood-2012-05-430959. Epub 2012 Oct 16.

47.

AID activity in B cells strongly correlates with polyclonal antibody affinity maturation in-vivo following pandemic 2009-H1N1 vaccination in humans.

Khurana S, Frasca D, Blomberg B, Golding H.

PLoS Pathog. 2012 Sep;8(9):e1002920. doi: 10.1371/journal.ppat.1002920. Epub 2012 Sep 13.

48.

Oligomeric recombinant H5 HA1 vaccine produced in bacteria protects ferrets from homologous and heterologous wild-type H5N1 influenza challenge and controls viral loads better than subunit H5N1 vaccine by eliciting high-affinity antibodies.

Verma S, Dimitrova M, Munjal A, Fontana J, Crevar CJ, Carter DM, Ross TM, Khurana S, Golding H.

J Virol. 2012 Nov;86(22):12283-93. doi: 10.1128/JVI.01596-12. Epub 2012 Sep 5.

49.
50.

Use of human MonoMac6 cells for development of in vitro assay predictive of adjuvant safety in vivo.

Zaitseva M, Romantseva T, Blinova K, Beren J, Sirota L, Drane D, Golding H.

Vaccine. 2012 Jul 6;30(32):4859-65. doi: 10.1016/j.vaccine.2012.05.002. Epub 2012 May 15.

PMID:
22609036

Supplemental Content

Loading ...
Support Center